Merck & Company, Inc. vs Intellia Therapeutics, Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and Intellia Therapeutics, Inc. (NTLA) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. scores ahead of Intellia Therapeutics, Inc. on Q·Score (7 vs 5.6 out of 10), led by Quality (7.7 vs 1.6) and Growth (6.2 vs 4.7). Intellia Therapeutics, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for NTLA (+70.0%) than for MRK (+13.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 19% return on equity and 14% profit margins.
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-56%).
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs NTLA: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Intellia Therapeutics, Inc. (NTLA) at 5.6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or NTLA?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 4.7/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while Intellia Therapeutics, Inc. reports (-9.5% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or NTLA more attractively valued?
Intellia Therapeutics, Inc. (NTLA) scores higher on Valuation (6.9/10 vs 6.7/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs NTLA?
There are 27 analysts covering MRK with a consensus price target of $129.74, and 19 analysts covering NTLA with a consensus target of $26.63. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or NTLA?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 1.6/10). Net profit margin: MRK at 13.6%, NTLA at 0.0%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or NTLA?
Intellia Therapeutics, Inc. (NTLA) scores higher on Financial Health (9.7/10 vs 7/10). Market beta: MRK at 0.22, NTLA at 1.81. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and NTLA?
Merck & Company, Inc. (MRK) has a market capitalisation of $281.2B, while Intellia Therapeutics, Inc. (NTLA) has a market cap of $2.2B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or NTLA pay dividends?
MRK pays a dividend yield of 2.95%, while NTLA does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →